119 related articles for article (PubMed ID: 10405636)
1. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.
Desbene S; Van HD; Michel S; Tillequin F; Koch M; Schmidt F; Florent JC; Monneret C; Straub R; Czech J; Gerken M; Bosslet K
Anticancer Drug Des; 1999 Apr; 14(2):93-106. PubMed ID: 10405636
[TBL] [Abstract][Full Text] [Related]
2. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
4. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation.
Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C
Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard.
Papot S; Combaud D; Bosslet K; Gerken M; Czech J; Gesson JP
Bioorg Med Chem Lett; 2000 Aug; 10(16):1835-7. PubMed ID: 10969980
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy.
Thomas M; Rivault F; Tranoy-Opalinski I; Roche J; Gesson JP; Papot S
Bioorg Med Chem Lett; 2007 Feb; 17(4):983-6. PubMed ID: 17157009
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
9. Self-immolative anthracycline prodrugs for suicide gene therapy.
Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
[TBL] [Abstract][Full Text] [Related]
10. Development of dual-acting prodrugs for circumventing multidrug resistance.
Abu Ajaj K; Kratz F
Bioorg Med Chem Lett; 2009 Feb; 19(3):995-1000. PubMed ID: 19131246
[TBL] [Abstract][Full Text] [Related]
11. First enzymatically activated Taxotere prodrugs designed for ADEPT and PMT.
Bouvier E; Thirot S; Schmidt F; Monneret C
Bioorg Med Chem; 2004 Mar; 12(5):969-77. PubMed ID: 14980610
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT.
de Bont DB; Leenders RG; Haisma HJ; van der Meulen-Muileman I; Scheeren HW
Bioorg Med Chem; 1997 Feb; 5(2):405-14. PubMed ID: 9061205
[TBL] [Abstract][Full Text] [Related]
13. A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs.
Papot S; Combaud D; Gesson JP
Bioorg Med Chem Lett; 1998 Sep; 8(18):2545-8. PubMed ID: 9873577
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
Kars MD; Işeri OD; Gunduz U; Molnar J
Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
[TBL] [Abstract][Full Text] [Related]
15. Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT.
Kamal A; Tekumalla V; Krishnan A; Pal-Bhadra M; Bhadra U
ChemMedChem; 2008 May; 3(5):794-802. PubMed ID: 18247436
[TBL] [Abstract][Full Text] [Related]
16. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
17. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range.
Teodori E; Dei S; Quidu P; Budriesi R; Chiarini A; Garnier-Suillerot A; Gualtieri F; Manetti D; Romanelli MN; Scapecchi S
J Med Chem; 1999 May; 42(10):1687-97. PubMed ID: 10346921
[TBL] [Abstract][Full Text] [Related]
19. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
[TBL] [Abstract][Full Text] [Related]
20. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
